ÈËÉú¾ÍÊDz©

Öйú¿ÆѧԺ¹ãÖÝÉúÎïÒ½Ò©Ó뿵½¡Ñо¿ÔºÑо¿Ô±ÀîÖ¾Ô¶ÍŶӷ¢Ã÷ÈËÆê´øѪȪԴ¼ä³äÖʸÉϸ°û£¨hUCMSCs£©¿ÉÒÔͨ¹ýmTOR°ÐÏò;¾¶Ôö½øTFEBºËתλ¼¤»î×ÔÊÉÈÜøÌ幦Ч£¬£¬£¬£¬£¬£¬ïÔ̭ϸ°ûÄÚÀÛ»ýÍ»±äÂÑ°×ataxin-3µÄº¬Á¿£¬£¬£¬£¬£¬£¬Æ𵽸ÄÉÆÉñ¾­Ï¸°û¹¦Ð§£¬£¬£¬£¬£¬£¬Ôö½øÉñ¾­±¬·¢µÄ×÷Óᣡ£¡£Ïà¹ØÑо¿Ð§¹û¿ËÈÕÒÔTranscription factor EB-mediated mesenchymal stem cell therapy induces autophagy and alleviates spinocerebellar ataxia type 3 defects in neuronal cells modelΪÌâ½ÒÏþÔÚCell Death and DiseaseÉÏ¡£¡£¡£

¼¹ËèСÄÔÐÔ¹²¼Ãʧµ÷(Spinocerebellar ataxia£¬£¬£¬£¬£¬£¬SCA) ÊÇÒ»×éÓÉСÄÔ¼°Æä´«ÈëºÍ´«³öÅþÁ¬±äÐÔÒýÆðµÄ³£È¾É«ÌåÏÔÐÔÒÅ´«ÐÔ¹²¼Ãʧµ÷¼²²¡£¡£¡£¬£¬£¬£¬£¬£¬Ö÷ÒªÌåÏÖΪÂýÐÔ¾ÙÐÐÐÔ¼ÓÖصĹ²¼Ãʧµ÷£¬£¬£¬£¬£¬£¬ÁÙ´²ÌåÏÖ°üÀ¨×ËÊƺͲ½Ì¬µÄÒì³£¡¢¹¹ÒôÕÏ°­¡¢ÑÛÇòÔ˶¯ÕÏ°­¡¢ÊÓÍøĤ²¡±ä¡¢ÖÜΧÉñ¾­Ë𺦵ȡ£¡£¡£ÖÁ½ñÈÔȱ·¦×èÖ¹¸Ã¼²²¡Ï£ÍûµÄÓÐÓÃÖÎÁÆÒªÁì¡£¡£¡£ÏÖÔÚÖ÷ÒªÖÎÁÆÊÖ¶ÎÊǶÔÖ¢ÖÎÁÆ»º½âÖ¢×´£¬£¬£¬£¬£¬£¬¹Ê¸Ã¼²²¡¾ßÓнϸߵÄÖÂËÀ¡¢Ö²ÐÂÊ¡£¡£¡£¼¹ËèСÄÔÐÔ¹²¼Ãʧµ÷3ÐÍ(Spinocerebellar ataxia type 3£¬£¬£¬£¬£¬£¬SCA3) Ò²³ÆΪÂí²é¶à-Լɪ·ò²¡( Machado-Joseph disease£¬£¬£¬£¬£¬£¬MJD)£¬£¬£¬£¬£¬£¬ÊÇÈ«ÌìÏ¡¢Ò²ÊÇÎÒ¹ú×î³£¼ûµÄ¼¹ËèСÄÔÐÔ¹²¼Ãʧµ÷ÑÇÐÍ£¨ÔÚÎÒ¹úÔ¼Õ¼63%£©£¬£¬£¬£¬£¬£¬ÊÇÓÉATXN3»ùÒòÖбàÂë¾Û¹È°±õ£°·µÄCAGÐòÁÐÒì³£Öظ´À©ÔöËùÖ¡£¡£¡£ÒÑÓжàÏîÑо¿Åú×¢SCA3»¼ÕßÉñ¾­Ôª¹¦Ð§Ëðº¦ÔçÓڽṹË𺦣¬£¬£¬£¬£¬£¬ÌáÐѶÔÉñ¾­Ôª¹¦Ð§µÄ¸ÉÔ¤¿ÉÄÜ¿ÉÒÔ¸ÄÉÆSCA3¼²²¡Ö¢×´¡£¡£¡£

¼ä³äÖʸÉϸ°û£¨MSCs£©ÖÎÁƶÔÉñ¾­ÏµÍ³¾ßÓнÏΪÃ÷È·µÄµ÷ÀíºÍÐÞ¸´×÷Óã¬£¬£¬£¬£¬£¬ÎªÉîÈëÊìϤ²¢ÆÊÎö¸Éϸ°ûÔÚÖÎÁÆSCA¼²²¡·½ÃæµÄ»úÖƼ°ÆäÖ÷ÒªÒâÒ壬£¬£¬£¬£¬£¬¸ÃÑо¿Í¨¹ý½«SCA3»¼ÕßµÄÄòÒºÉÏƤϸ°ûÖرà³ÌΪ¶àÐÑĿϸ°ûiPSCs£¬£¬£¬£¬£¬£¬°ÑiPSCs·Ö½âÓÕµ¼µ½Éñ¾­Ôª½×¶Î¡£¡£¡£Í¨¹ýÂÑ°×ÃâÒßÓ¡¼£ÊµÑé·¢Ã÷£¬£¬£¬£¬£¬£¬¸ÃSCA3Éñ¾­ÔªÖб£´æÍ»±äÂÑ°×ataxin-3µÄ±í´ïºÍ»ýÀÛ£¬£¬£¬£¬£¬£¬²¢ÇÒÆäÖÐ×ÔÊÉˮƽÏÔÖøµÍÓÚÕý·²È˱ÈÕÕ×é¡£¡£¡£ÔÚ¾­ÓÉMSCs¹²×÷ÓýÖÎÁƺó£¬£¬£¬£¬£¬£¬²¡ÈË×é×ÔÊÉÂÑ°×ULK1£¬£¬£¬£¬£¬£¬Beclin1ºÍLC3-IIµÄ±í´ïˮƽ¾ùÏÔÖøÉý¸ß£¬£¬£¬£¬£¬£¬¶øÍ»±äÂÑ°×ataxin-3µÄ±í´ïÔòÏÔ׎µµÍ£¬£¬£¬£¬£¬£¬·´Ö®£¬£¬£¬£¬£¬£¬ÍâÃÚÌåÒÖÖƼÁGW4869¼°×ÔÊÉÒÖÖƼÁ3-MA¿ÉÒÔÄæת¸ÃÇ÷ÊÆ£¬£¬£¬£¬£¬£¬µ¼ÖÂÍ»±äµÄataxin-3ÂÑ°×ÔÚϸ°ûÄÚÏÔÖøÔöÌí¡£¡£¡£¸ÃÑо¿½øÒ»²½·¢Ã÷hUCMSCs¹²×÷ÓýÖÎÁÆ¿ÉÔö½ømTORC1ÓëTFEBÊèÉ¢£¬£¬£¬£¬£¬£¬Ôö½øCa2+´ÓÈÜøÌåÊÍ·Å£¬£¬£¬£¬£¬£¬µ¼ÖÂTFEBÍÑÁ×Ëữ£¬£¬£¬£¬£¬£¬Ò×λÖÁϸ°ûºËÄÚÓëCLEARÐòÁÐÁ¬Ïµ£¬£¬£¬£¬£¬£¬Éϵ÷×ÔÊɺÍÈÜøÌå»ùÒò¡£¡£¡£Í¬Ê±£¬£¬£¬£¬£¬£¬Ñо¿Ö°Ô±Í¨¹ý¹¹½¨TfebÂý²¡¶¾×ÌÈź͹ý±í´ïÖÊÁ£À´ÒÖÖƺͼ¤»îÉñ¾­ÔªÖÐTfeb»ùÒòµÄ±í´ï£¬£¬£¬£¬£¬£¬ÊµÑéЧ¹ûÅú×¢£¬£¬£¬£¬£¬£¬Tfeb»ùÒòÊÇhUCMSCs¹²×÷ÓýÖÎÁƼ¤»î×ÔÊÉÈÜøÌå;¾¶µÄÒªº¦µ÷ÀíÒò×Ó£¬£¬£¬£¬£¬£¬Ò²ÊÇÔö½øÍ»±äÂÑ°×ataxin-3½µ½âµÄÖ÷Òª°Ðµã¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬¸ÃÑо¿»¹·¢Ã÷hUCMSCs¹²×÷ÓýÖÎÁÆ¿ÉÒÔͨ¹ýÒÖÖÆPI3K/AKTµÄÁ×Ëữ£¬£¬£¬£¬£¬£¬ÒÔ¼°¼¤»îAMPKµÄÁ×ËữÀ´ÒÖÖÆmTORC1£¬£¬£¬£¬£¬£¬½µµÍmTORC1ºÍTFEBÖ®¼äµÄÏ໥×÷Óã¬£¬£¬£¬£¬£¬Ôö½øTFEBÈ¥Á×ËữÒÔ¼°ºËת룬£¬£¬£¬£¬£¬´Ó¶ø¼¤»îϸ°û×ÔÊÉ£¬£¬£¬£¬£¬£¬½µ½âϸ°ûÄÚµÄÍ»±äÂÑ°×ataxin-3£¬£¬£¬£¬£¬£¬¸ÄÉÆSCA3²¡ÈËÉñ¾­ÔªµÄÉú³¤ºÍÉñ¾­Ï¸°û¹¦Ð§£¬£¬£¬£¬£¬£¬Ôö½ø²¡ÈËÉñ¾­ÔªÉñ¾­ÍøÂçµÄÐγɡ£¡£¡£

¸ÃÑо¿ÎªÌ½Ë÷SCA3¼²²¡µÄ·¢²¡»úÖƺÍÖÎÁƵÓÚ¨ÁËʵÑé»ù´¡£¡£¡£¬£¬£¬£¬£¬£¬²¢ÎªSCA3¼²²¡ºÍÆäËûÉñ¾­ÍËÐÐÐÔ¼²²¡µÄÖÎÁÆÌṩÁËÒ»¸öÐÂÕ½ÂÔ¡£¡£¡£

¸ÃÑо¿»ñµÃÁ˹ú¼Ò×ÔÈ»¿Æѧ»ù½ð¡¢¹ã¶«Ê¡×ÔÈ»¿Æѧ»ù½ðºÍ¹ãÖÝÔÙÉúҽѧÓ뿵½¡¹ã¶«Ê¡ÊµÑéÊÒÇ°ÑØ̽Ë÷ÏîÄ¿µÄ×ÊÖú¡£¡£¡£

ȪԴ£ºÖйú¿ÆѧԺ¹ÙÍø